Dynavax Technologies Corporation
  1. Companies
  2. Dynavax Technologies Corporation
  3. News
  4. Dynavax to Present at the Cowen 42nd ...

Dynavax to Present at the Cowen 42nd Annual Health Care Conference

SHARE
Feb. 22, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, at 2:50 p.m. E.T.

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "investors" section of the Company`s website at.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines to help protect the world against infectious diseases. The Company`s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal influenza.

Contact supplier

Drop file here or browse